OneDigital Investment Advisors LLC Boosts Holdings in ProQR Therapeutics (NASDAQ:PRQR)

OneDigital Investment Advisors LLC raised its holdings in shares of ProQR Therapeutics (NASDAQ:PRQR) by 37.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 57,550 shares of the biopharmaceutical company’s stock after buying an additional 15,550 shares during the period. OneDigital Investment Advisors LLC owned about 0.07% of ProQR Therapeutics worth $105,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Privium Fund Management B.V. grew its position in shares of ProQR Therapeutics by 0.9% during the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after acquiring an additional 51,663 shares during the period. Ikarian Capital LLC grew its holdings in ProQR Therapeutics by 2.3% during the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after purchasing an additional 10,958 shares during the period. BNP Paribas Financial Markets increased its position in ProQR Therapeutics by 120.1% in the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 19,100 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of ProQR Therapeutics in the first quarter worth about $56,000. Finally, EP Wealth Advisors LLC purchased a new position in shares of ProQR Therapeutics during the 1st quarter valued at about $26,000. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Trading Up 0.3 %

NASDAQ PRQR opened at $3.62 on Friday. ProQR Therapeutics has a 12 month low of $1.18 and a 12 month high of $4.62. The stock has a market cap of $295.68 million, a PE ratio of -11.31 and a beta of 0.26. The stock’s 50 day moving average is $2.90 and its 200 day moving average is $2.23.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. HC Wainwright raised their price objective on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $7.13.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).